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Abstract: Hypoxia adversely affects cells and tissues, and neuronal cells in particular have been shown to be
more susceptible to the injurious effects of hypoxia in which they may begin to die when oxygen supply is
reduced or completely eliminated. Cannabinoid (CB1) receptor agonists have been shown to elicit several
Central Nervous System (CNS) effects, mediated via G protein-coupled receptors. The aim of this study was
to examine the effect of hypoxia on G protein coupled receptor (CB1) gene expression in cortical neuronal B50
cell lines in culture. The B50 cells were cultured in normoxia (21% O2; 5% CO2) and hypoxia (5% O2; 5%
CO2), and were treated with cannabinoid agonists to determine their effects on hypoxia-induced changes. Three
cannabinoid agonists [Win55,212-2 mesylate (Win), arachidonoylethanolamide (AEA) and 2-
arachidonylglycerol (2-AG)], were administered to the cells as treatment for 48 hours after 48hours of initial
culture for a total of 96hours of culture in hypoxic conditions at concentrations of 10, 50 and 100 nM. The
levels of G-protein coupled receptor (CB1) mRNAs were assessed using RT-PCR. The results showed that
hypoxia induced morphological changes in B50 cells in hypoxia while the CB1 RT-PCR mRNA levels showed
no appreciable changes in normal, hypoxic and treated cells. The results show that B50 neuronal cells are
susceptible to damage and injurious effects of hypoxia, as are most brain cells and the cannabinoid agonist
treatments showed there were no changes in the level of CB1 receptor gene expression due to hypoxia or agonist
treatment in neuronal B50 cells in culture.
Key words: Cannabinoid (CB1) receptor, cannabinoid agonist, G-protein coupled receptor, hypoxia,
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INTRODUCTION
Cannabinoid (CB1) receptors are concentrated mainly
in the cerebellum and the basal ganglia, as well as in the
hippocampus   and    the   amygdala   (Gardner, 2006;
Begg et al., 2005). CB1 receptors are predominantly found
in the neurons of the Central Nervous System (CNS) and
the B50 neuronal cells are derived from the CNS neurons
(Matsuda et al., 1990; Soderstrom and Johnson, 2000). A
second cannabinoid receptor was initially detected in
spleen cells, white blood cells, and other tissues
associated with the immune system. This second receptor
is called the CB2 receptor and is mainly present in the
peripheral system (Munro et al., 1993). William Devane
and colleagues were the first to identify the original
endogenous cannabinoid called arachidonyl ethanolamine
(AEA), or “anandamide” (Devane et al., 1992). The AEA
is  a brain-derived  lipid  that  binds  to cannabinoid
receptors and mimics the biological effects of )9-THC
(Begg et al., 2005). Some years later, the second
endocannabinoid  was  isolated  from  the  intestinal tract
and  brain,  called  2-arachidonoylglycerol  (2-AG)
(Sugiura et al., 1995). 
The biological effects of endogenous, plant-derived
and synthetic cannabinoids are mediated through specific
G protein coupled cannabinoid (CB) receptors. The CB1
receptor is highly conserved in mice, rats and humans
while    the    CB2    receptors   are   more   divergent
(Begg et al., 2005). Both CB1 and CB2 receptors are
coupled through Gi/o proteins to inhibit adenylyl cyclase
and regulate calcium (9) and potassium (8) channels
(Begg et al., 2005; Mackie, 2006). In tissues naturally
expressing CB receptors and in transfected cell lines, CB1
and CB2 receptors have been shown to have a high level
of ligand-independent activation (Begg et al., 2005). It
has been shown that in the population of wild-type CB1
receptors, only about 30% exists in the activated form
while  70%  are  inactive  (Kearn et al., 1999; Carter and
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Weydt, 2002). Some of the CB1 receptors exist in
inactivated form within the cytosol and are in GDP-bound
state while some exist in  a  tonically  activated state and
are coupled to active G-proteins  within   the   plasma
 membrane  in their GTP-bound state (Vásquez and
Lewis, 1999; Nie and Lewis, 2001). It has been shown
that in their activated state, the receptors have a higher
affinity for the cannabinoid agonists (Vásquez and Lewis,
1999; Nie and Lewis, 2001). The human CB2 receptors
show 68% amino acid homology with the CB1 receptors
in the transmembrane domains and a 44% overall
homology (Munro et al., 1993; Begg et al., 2005).
However, despite the low level of homology between the
two receptors, their pharmacology is similar with most
plant-derived, endogenous and classical synthetic
cannabinoids having similar affinities for the two
receptors (Showalter et al., 2005; Begg et al., 2005),
although synthetic agonists with greater than 100-fold
affinity for CB1 or CB2 receptors have been developed
(Hillard et al., 1997; Malan et al., 2001). Both CB1 and
CB2 receptors are the primary targets of endogenous
cannabinoids and they play important role in many
processes, including metabolic regulation, craving, pain,
anxiety,   bone   growth,   and   immune  function
(Mackie, 2006). There is evidence of agonist selectivity
for CB1 receptors coupled to different subtypes of Gi
proteins or to Gi versus G@ proteins (Howlett, 2004 ).
Reverse Transcription (RT) Polymerase Chain Reaction
(PCR), is a laboratory method used for amplifying a piece
of ribonucleic acid (RNA) molecule (Prasad et al., 2001).
The RNA strand is first reverse-transcribed into its
deoxyribonucleic acid (DNA) complement or
complementary DNA, followed by amplification of the
resulting  DNA  using  a polymerase chain reaction
(Prasad et al., 2001). The RT-PCR based assay is one of
the most common methods for characterizing and
confirming gene expression patterns using messenger
ribonucleic acid (mRNA) in different sample populations
(Orlando et al., 1998;  Bustin, 2002). The amplification of
RNA using RT-PCR provides for a highly sensitive
technique, where a very low copy number of RNA
molecules can be detected and is widely used in the
diagnosis of genetic diseases and, as a measure of gene
expression (Nolan et al., 2006; Burdyga et al., 2004).
Accurate determination of total RNA concentration is
important for the quantification of mRNA levels. The RT
is important for sensitive and accurate quantification and
the amount of cDNA produced by the reverse
transcriptase accurately represents the RNA input
(Gnanapavan  et  al.,  2002;  Wall  and  Edwards, 2002;
Liu et al., 2002). The RT-PCR quantification of mRNA
has  been  used  to  monitor  transcription  in vitro and
direct  detection  of  the  effects  of receptor signalling
(Liu et al., 2002; Yuen et  al., 2002; Cohen  et al., 2002).
The RT-PCR method has also been used to study the
effects of some experimental agents on the expression of
cannabinoid receptors in whole animal and culture
conditions  (Lalonde  et  al.,  2006; Chen et al., 2005;
Zhang et al., 2006). The aims of the present work were to
investigate the expression of cannabinoid (CB1) receptor
gene in B50 neuronal cells. To investigate the effect of
hypoxia on the expression of cannabinoid (CB1) receptor
gene on B50 neuronal cells and to investigate the effect of
cannabinoid receptor agonist treatment on cannabinoid
(CB1) receptor gene in cultured B50 cells using semi
quantitative RT-PCR.
MATERIALS AND METHODS
Neuronal culture: One group of B50 neuronal cells were
cultured and maintained in a normoxic incubator (21%O2;
5% CO2) as control group and another batch cultured
under hypoxia (5% O2; 5% CO2) as experimental group.
Cells were cultured in 12-well culture plates for 48 hours
and three cannabinoid receptor agonists: Win55, 212-2
m e s y l a t e  ( W i n ) ,  a n a n d a m i d e  o r
arachidonoylethanolamide (AEA),  and 2-
arachidonylglycerol (2-AG), and antagonists were
administered to the cells as treatment against hypoxia for
48 hours for a total of 96 hours at a concentration of 10,
50 and 100 nM. The total cellular RNA was extracted
from the cultured B50 neuronal cells using the TRIzol
reagent method (Invitrogen No 15596-026), as outlined
below. The cells were cultured at the cell culture
Laboratory of Queen Margaret University Edinburgh and
the RT-PCR was done at the Centre for Neuroscience,
University of Edinburgh United Kingdom in 2006. 
Method: The B50 cells in different experimental groups
were grown and lysed in culture plates by adding 0.5ml of
TRIzol reagent to each well. The cells were homogenized
and incubated for 5 min at room temperature. The
homogenates were transferred to micro-centrifuge tubes,
0.1 mL of chloroform added, the cap secured and the
tubes shaken vigorously by hand for 15 sec. The cellular
mixture was incubated at room temperature for 3 min. The
mixture was then centrifuged at 12,000 x g for 15 min at
room temperature. Following centrifugation, the mixture,
separated into 3-layers namely a lower phenol-chloroform
phase (Red), a middle interphase (Cloudy) and an upper
aqueous colourless phase.
The RNA was present at the upper aqueous
colourless phase and formed about 60% of the total
volume of the mixture and was transferred to a fresh
micro-centrifuge tube. The aqueous phase was mixed with
0.25 mL of isopropyl alcohol and incubated for 10 min at
room temperature. The mixture was then centrifuged at
12,000 x g for 10 min at room temperature. At this point
the RNA precipitated and formed a gel-like pellet.
The supernatant was removed and the remaining
RNA pellet was washed once with 0.5 mL of 75% ethanol
and mixed by vortexing. The mixture was centrifuged at
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7,500 x g for 5 min at room temperature and the ethanol
was decanted. The RNA was then air dried for 10 min,
dissolved in 100% deionized formamide and stored at -
70ºC to be used in RT-PCR analysis.
Semi-quantitative one step RT-PCR analysis: The
extracted total RNA, Superscript III RT/Platinum Taq
Mix, Reaction Mix, 5 nM Magnesium Sulphate,
GeneAMP PCR System thermal cycler were used
according to the manufacturer’s instruction. The CB1
primers, sense 5’-GAT GTC TTG GGA AGA TGA ACA
AGC-3’ (nt 365-373) and antisense 5’-AGA CGT GTC
TGT GGA CAC AGA CAT GG-3’ (nt 460-468). The
primers were selected from Esposito et al. (2002), since
they were used for the study of CB1 expression and the
effect of cannabinoid agonist treatment in neuronal glial
cells. Alpha actin primer Sense  5’-GAT CAC CAT CGG
GAA TGA ACG C-3’  (389bp) and Antisense 5’-CTT
AGA AGC ATT TGC GGT GGA C-3’, selected from
Park et al. (1997), where they were used as an internal
control for cytoskeletonal study in pericytes.
Programming of the thermal cycler was done as
follows:  cDNA synthesis 1 cycle at 55ºC for 30 min,
Denaturation 1 cycle at 94ºC for 2 min, PCR
amplification 40 cycles at 94ºC for 15 sec (Denature),
60ºC for 30 sec (Anneal), 68ºC for 60 sec (Extend), Final
extension, 1 cycle at 68ºC for 5 min. 
The master mix was prepared on ice using 0.2 mL
nuclease free, thin walled PCR tubes. Each PCR tube
contained the following: 2 x Reaction mix (dNTPs: 200
:M; MgSO4: 1.6 mM) 25:L, Template RNA (200 ng/:L)
1:L, Sense Primer (0.2:M), 1 :L, Antisense Primer (0.2
:M)1 :L, SuperScript III RT/ Platinum Taq mix (5 mM)
2 :L, Autoclaved distilled water; 20 :L was added to
make up total volume to 50 :L.
These were mixed together gently and all the
components were allowed to settle at the bottom of the
amplification tube. The tubes were then centrifuged
briefly by pulse centrifugation, over-laid with one drop of
mineral oil and placed in a preheated thermal cycler
(GeneAMP PCR System) as programmed above. One
tube was used as blank and contained only master mix
and water.
Analysis of the RT-PCR products: The analysis of the
PCR products was carried out using the following
method. Agarose gel (2%) was made by dissolving 2.5 g
agarose in 112.5 mL of distilled water which was
subsequently micro-waved in a conical flask for 5 min.
12.5 mL buffer solution of Tris/Borate/EDTA (TBE) was
added and 5 :L of ethidium bromide added for staining
the mRNA and mixed thoroughly. The mixture was
poured into the gel tray with combs in place and air
bubbles pushed to the sides with a pipette. The gel was
allowed one hour to set. 5 :L of Blue loading buffer
(Sigma, G7654), which contain bromphenol blue (0.25%
w/v), xylene cyanole FF (0.25% w/v), sucrose (40% w/v),
was added to each of the samples and centrifuged briefly
to mix and settle. 
A 10 :L DNA ladder (Promega, G2101) and 5 :L
Blue loading buffer was used to make-up the DNA
marker, and 1 L of gel buffer was made using the TBE in
a 1:10 dilution. The gel was placed in an electrophoresis
tank with wells at the negative electrode such that RNA
will move towards the positive electrode. The gel was
then surrounded with gel buffer and the wells completely
covered by the buffer. The DNA marker (5 :L), was
added to the gel on position one, followed by adding a 10
:L blank sample to the next position, and continuing to
add 10 :L of each sample to the remaining wells. The
electrophoresis tank was connected to a power supply set
at 125 V for 1 h. Photographs of the gels were taken and
scanned using the digital densitometer to evaluate and
semi-quantify the mRNA of the receptors, and then
compared between the different groups.
Statistical analysis: The different parameters measured
from the normal, hypoxic and treated experimental groups
of B50 neuronal cells were compared using mean and
standard deviation (SD). The parameters were assayed in
triplicate and repeated twice (n = 6) and the results
presented as the mean±SD. The Students’t-test was used
for testing the level of significance between two groups
and a P-value less than 0.05 was considered to be
significant using Microsoft Excel® package. For multiple
treatment data, One-Way analysis of variance (ANOVA)
was used followed by Multiple Range Test post hoc
subgroup testing to find the least significant difference
(LSD) between the groups. 
RESULTS
Morphological changes were observed in B50 cells
cultured under hypoxia when compared to cells cultured
in normoxia. The B50 cells in hypoxia showed clustered
groups of neuronal B50 cells, evidence of degenerating,
dying cells and already degenerated and dead neuronal
B50 cells. The normal B50 neuronal cells cultured under
normal incubator showed normal neuronal morphology
(Plate 1 and 2), when compared to B50 cells in hypoxia
(Plate 3 and 4).
The effect of hypoxia on the expression of CB1
receptor gene in B50 cells: The result of CB1 receptor
gene expression in B50 neuronal cells in normal, hypoxic
and treated cells was studied using reverse transcription
polymerase chain reaction (RT-PCR) (Fig. 1). The results
showed that the RT-PCR experiments with the B50
neuronal cells in normal, hypoxic and treated cultures
demonstrated positive gene expression of the cannabinoid




Plate 1: Representative  of B50  cells  at  other with normal B50 cells (arrow) at the point of starting the culture at 21% O2 and 5%
CO2. B50 cells were observed in three different plates with same field method in a quadri-point analysis under the Nikon
Eclipse TS100 microscope and microphotographs processed with an IBM Image Solutions®. Scale bar=5mm×40
magnification.
Plate 2: Representation of B50 cells at 48hrs of normal culture (21% O2 and 5% CO2) with B50 cells (arrow). B50 cells were
observed tn three different plates with same field method in a quadri-point analysis under the Nikon Eclipse TS 100
microscope and microphotographs processed with IBM Image Solution® . Scale bar=5mm×40 magnification
CB1 receptors. The mRNA levels of CB1 receptors in
hypoxic culture of B50 cells were expressed relative to
CB1 receptors in B50 cells cultured under normal
conditions, and these were also compared with mRNA
levels of CB1 receptors in hypoxic B50 cells treated with
different receptor agonists (Fig. 2). The results showed
that there were no significant difference in the levels of
CB1 receptor gene and mRNA expression between the
normal, hypoxic and agonist treated cultured B50 cells.
Semi quantitative RT-PCR of cannabinoid CB1: CB1
receptor gene expression products were subjected to semi
quantitative analysis using digital densitometric
measurements. The result showed a significant decrease
(p<0.05)  in the density of the RT-PCR products of CB1
in hypoxic cells  treated  with  100 nM AEA (85%) and
10 nM 2-AG (80%) agonists when compared with normal
cultured B50 cells (100%), while the increase of 102, 101,
107, 104  and 104% in untreated hypoxic cells and cells
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Palate 3: Representative of hypoxic B50 cells at 96 hrs of culture (5% O2 and 5% CO2) with groups of degenerating cells (black
arrow) and altered pattern of cells arrangement (blue arrow). Groups of degenerating and altered nerve arrangement were
observed in six different plates with same field method in a quadri-point analysis under the Nikon Eclipse TS 100
microscope and microphotographs processed with an IBM Image Solutions ®. Scale bar=5mm×40 magnification
Plate 4: Representative of hypoxic B50 cells 96hrs of culture (5% O2 and 5% CO2) with groups of degenerating cells (black arrow)
and altered pattern of cell arrangement (blue arrow). Groups of degenerating and altered nerve arrangement were observed
in six different plates with same field method in a quadri-point analysis under the Nikon Eclipse TS 100 microscope and
microphotographs processed with an IBM Image Solution ®. Scale bar=5mm×40 magnification 
treated with 10 nM Win, 50 nM Win, 10 nM AEA and 50
nM AEA, were not significantly different from the control
(100%). The decrease in the density of CB1 receptors with
100 nM Win (97%); 50 nM 2-AG (92%) and 100 nM 2-
AG (95%), was not significant when compared with the
control. There was no significant change in densitometric
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Fig 1: The effect of hypoxia and cannabinoid treatment on CB1 receptor expression in B50 cells
A: DNA Ladder; B = Normal B50 cells; C = Hypoxic B50 cells;
D-I = Hypoxic treated cells with different cannabinoid agonist;
J-M = Hypoxic cells treated cannabinoid agonist/antagoinst;
I = Alpha actin
Fig. 2: The effect of hypoxia on the expression density of CB1 receptor in B50 cells
Table 1: Semi-Quantitative RT-PCR product of CB1 receptor gene in B50 cells in culture
TreatmentType Vol.mm3 Areamm2 STD  ± Density Width Height Normal (%) Control (%)
CB1Norma 09.61 4.17 0.39 571.41 1.40 2.98 100 110.0
Hypoxia 15.75 6.66 0.33 586.22 1.78 3.75 102.59 112.85
10nM Win 12.32 5.24 0.33 577.20 1.58 3.36 101.01 111.12
50nM Win 10.59 4.28 0.35 612.24 1.77 2.40 107.15 117.86
100nM Win 6.35 2.83 0.35 555.37 1.21 2.35 97.19 106.91
10nM AEA 10.65 4.44 0.35 595.31 1.40 3.18 104.18 114.60
50nM AEA 5.91 2.60 0.35 595.31 1.40 3.18 104.18 93.98
100nM AEA 3.91 1.98 0.21 488.19 0.76 2.60 85.44* 83.37
10nM 2-AG 6.99 3.53 0.03 459.07 0.38 1.40 80.34* 101.53
50nM 2-AG 8.64 4.06 0.30 527.40 1.21 3.37 92.30 104.65
100nM 2-AG 8.90 4.06 0.31 543.60 1.21 3.37 95.13 104.65
Alpha actin 10.35 3.22 0.32 519.46 2.02 3.12 90.91 100
measurements of mRNA area, mRNA volume, height and
width respectively when compared with the control B50
cells (Table 1).
When the density of the RT-PCR products was
normalised to alpha actin (100%), there was no observed
difference in the levels of the receptor gene mRNA
expression of CB1 in normal, hypoxic and treated cultured
B50 cells. The results showed no significant difference
between the normal (CB1) cultured B50 cells (110%),
untreated hypoxic cells (112%) and hypoxic treated cells
with 10 nM Win (111%); 50 nM Win (117%); 100 nM
Win (106%); 10 nM AEA 114%; 50 nM 2-AG (101%).
The CB1 receptor density showed a non-significant
decrease with the cells treated with 100 nM AEA (93%)
and 10 nM 2-AG (83%), when compared to those of alpha
actin (100%) (Fig. 2). 
DISCUSSION
The results from the present work showed the cortical
B50 neurons cultured under normoxia, hypoxia and
hypoxia treated with cannabinoid agonist and antagonist,
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positively showed G protein coupled (CB1) receptor gene
expression using RT-PCR method. The results also
demonstrated that there was no appreciable change in the
levels of CB1 receptor mRNA expressed. The effect of
cannabinoid receptor agonist treatment on the morphology
of B50 cells showed changes in the morphology of the
B50 cells cultured in hypoxia when compared to the
normal and untreated hypoxic B50 cells. The changes in
the morphology could be correlated with changes in
viability and LDH leakage from the B50 cells, results not
shown here. Some of the results show significant
increases in the presence of the antagonist, suggesting that
the actions of the agonists may be mediated through both
receptor- and non-receptor-mediated pathways in these
cells. The mediation through the cannabinoid (CB1)
receptors in this process occurs via the activation of G"i/o
proteins. This could explain why the hypoxic and hypoxic
treated cells both showed positive expression of the CB1
receptor genes though some of the cells are dying and
degenerating in culture and the effects of hypoxia
differentially affected them. Aguado et al. (2007) have
shown that the CB1 receptors mediate excitotoxicity-
induced neural progenitor proliferation and neurogenesis.
It has been shown that the endocannabinoid system exerts
an important neuro-modulatory function in different brain
tissues and is known to be involved in the regulation of
neural cell fate (Galve-Roperh et al., 2007). There is the
presence of a functional endocannabinoid system in
neural  progenitor  cells  that  participates  in the
regulation  of  cell  proliferation  and  differentiation
which   play   a   regulatory   role   in  neurogenesis
(Galve-Roperh et al., 2007).
The endocannabinoid system has been shown to
affect early progenitors and this extends to the regulation
of neuronal migration and the attainment of the
morphological, physiological and molecular
characteristics that occur during terminal neuronal
differentiation (Harkany et al., 2007). It has also been
shown that AEA and Win, with brain-derived
neurotrophic factor, induce the migration of GABA-
containing interneurons that undergo migration to
populate the embryonic cortex (Harkany et al., 2007). The
activation of the CB1 receptors in which downstream
signalling  events  such  as  proliferation and
differentiation occur, exert profound effects on neurite
outgrowth and synaptogenesis (Harkany et al., 2007;
Berghuis et al., 2004; Berghuis et al., 2005). The
cannabinoid agonist, HU210 promotes neurite outgrowth
in  Neuro  2A  cells  by  the  G"o/i-mediated  degradation
of Rap-GAPII and the subsequent activation of Rap1
(Jordan et al., 2005). These effects could be as a result of
the level of G protein Coupled receptor (CB1) gene
expression in B50 cells.
The results of the present study showed some
consistency with other studies showing that the different
cannabinoid receptor agonists used acted through the G
protein coupled receptors (GPCRs) to mediate cellular
activities, functions and alterations via the intracellular
second messenger pathway. These cellular activities such
as proliferation and differentiation were shown to increase
in the cells treated with the cannabinoid agonists when
compared with the untreated hypoxic B50 cells in culture
(Zhuang et al., 2001). 
The involvement of CB1 receptors in cannabinoid
neuroprotective effects of Win and AEA, was because of
the ability of the cannabinoid antagonists to inhibit the
protection from the agonists, thus pointing to a Gi/o-
mediated mechanism. This is because exogenous
cannabinoids have been shown to protect against
neurotoxicity  in  a  number  of  different  cellular, animal
and human   experimental   models  (Pryce  et al., 2003;
Davies et al., 2002; Wang et al., 2007). Zhang et al.
(2005) have demonstrated that cultured rat hippocampal
neurons were protected from excitotoxic insults by pre-
treatment with either )9-THC or Win and these
compounds were effective in preventing cell death even
if administered prior to the neurotoxic exposure. The
results presented here showed that the CB1 mRNA
expression thus the CB1 gene expression were unrelated
to the levels of protection exerted by cannabinoid
agonists. Thus, the results of CB1 gene expression in B50
neurons are likely the result of more complex interactions
within these B50 cells. It is possible to reflect that CB1
receptors are found in the cerebral cortex especially in the
medial frontal cortex. Hence input from the cortex affects
gene expression in other neurons (Steiner et al., 1999),
and a study indicates that cortical activation may
preferentially increase gene expression in striato-pallidal
neurons (Steiner et al., 1999). Therefore, it is conceivable
that altered inputs from the cortex, or other brain areas,
contribute to changes in gene  expression  in the striatum
in CB1 mutants (Steiner et al., 1999).
Three mechanisms could be attributable to the
reactions of the agonists used in this study. The G protein
coupled receptors involved could be over activated,
desensitized or saturated. Thus at higher concentrations of
cannabinoid administration, the receptors could either
become over-activated, desensitized or become saturated
and hence leading to the higher concentrations of the
drugs not resulting in higher response to the drug action.
It could also be that at higher concentrations of the drugs,
the receptors become highly activated and hence cell
death could result, leading to elevated LDH release from
the B50 cells in culture. The mechanism involved could
also be that the receptor stimulation by higher
concentrations of the agonists evoked Ca2+ release from
the endoplasmic reticular stores followed by Ca2+ influx
through store-operated Ca2+ channels in the plasma
membrane (Chang et al., 2007). This effect could also be
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an example of a specialized functional homologous or
heterologous desensitization of the CB1 receptors in
higher concentrations of the agonists which induces
interference on the receptor-induced activities. This is
because Van-Ham and Oron (2005) have shown that G"o
G-proteins mediate both homologous and heterologous
rapid desensitization of responses mediated by G-protein-
coupled receptors (Downer et al., 2003; Sarne and
Mechoulam, 2005). 
The cannabinoid agonist-induced stimulation of CB1
receptors leading to cannabinoid receptor-mediated
stimulatory effect on cAMP accumulation in the cells is
through the G"s (Glass and Felder, 1997). The
cannabinoid-induced increase in cAMP accumulation in
B50 cells when compared to untreated hypoxic cells,
results not shown, may lead to the increased down-stream
signalling activities such as proliferation and
differentiation in cannabinoid-treated cells, through a
combination of molecular signalling pathways in B50
cells (Yao et al., 2006). Most of the protectant effects of
cannabinoids appear to be mediated by the activation of
the cannabinoid (CB1) receptors (Grundy, 2002;
Mechoulam et al., 2002; Biegon, 2004). These effects
were blocked by the cannabinoid receptor antagonists
AM251 and AM630, suggesting both cannabinoid
receptor- and non-receptor-mediated mechanism.
Cannabinoids have been reported to protect neurons from
death caused by glutamatergic over-stimulation,
ischaemia and oxidative damage (Hansen et al., 2002).
These effects could have been due to the cannabinoids
having multiple effects on the G proteins mediated
responses (Slessareva et al., 2003). The differences
between the effects observed in different models may be
related to the cell type or model system used and the
differences in the toxic events which have been employed
(Chen   et   al.,   2005;   Drysdale   and  Platt,  2003;
Zhang et al., 2005). 
In conclusion, the present study shows that the RT-
PCR quantification of cannabinoid (CB1) receptor mRNA
can be used to monitor the receptor transcription in vitro
and direct detection of the effects of receptor signalling
during hypoxia in cultured B50 cells. The RT-PCR
method has also shown to be good in the study of the
effects of cannabinoid agonists in the expression of CB1
receptors in B50 cells in culture conditions. The results
from the present study showed that hypoxia induced
morphological changes in B50 cells in hypoxia while the
CB1 RT-PCR mRNA levels showed no appreciable
changes in normal, hypoxic and cells treated with
cannabinoid agonists. The results show that B50 neuronal
cells are susceptible to damage and injurious effects of
hypoxia, as are most brain cells and the cannabinoid
agonist treatments showed there were no changes in the
level of CB1 receptor gene expression due to hypoxia or
agonist treatment in neuronal B50 cells in culture.
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